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Regular Article
IMMUNOBIOLOGY
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Key Points
• Early-differentiated NK cells
accumulate and proliferate
during IM.
• These early-differentiated
NK cells preferentially
target lytic EBV-infected
B cells in vitro.
Agrowingbodyof evidencesuggests that thehumannatural killer (NK)-cell compartment
is phenotypically and functionally heterogeneous and is composed of several dif-
ferentiation stages. Moreover, NK-cell subsets have been shown to exhibit adaptive
immune features during herpes virus infection in experimental mice and to expand
preferentially during viral infections in humans. However, both phenotype and role
of NK cells during acute symptomatic Epstein-Barr virus (EBV) infection, termed in-
fectious mononucleosis (IM), remain unclear. Here, we longitudinally assessed the
kinetics, the differentiation, and the proliferation of subsets of NK cells in pediatric
IM patients. Our results indicate that acute IM is characterized by the preferential
proliferation of early-differentiated CD56dim NKG2A1 immunoglobulin-like receptor-
NK cells. Moreover, this NK-cell subset exhibits features of terminal differentiation and persists at higher frequency during at least
the first 6 months after acute IM. Finally, we demonstrate that this NK-cell subset preferentially degranulates and proliferates on
exposure to EBV-infected B cells expressing lytic antigens. Thus, early-differentiated NK cells might play a key role in the immune
control of primary infection with this persistent tumor-associated virus. (Blood. 2014;124(16):2533-2543)
Introduction
Natural killer (NK) cells are a subset of innate lymphocytes that
exhibit nonredundant antiviral functions in experimental mice.1 In
mice infected with the murine cytomegalovirus (MCMV), a subset
of NK cells bearing the activating receptor Ly49H expands and
persists at increased frequency for more than 2 months following
primary infection. Notably, these cells display an enhanced pro-
tective response against MCMV in adoptive transfer experiments.2
In humans, the peripheral blood compartment of NK cells is het-
erogeneous and accounts for 5% to 15% of lymphocytes. It is
composed of diverse differentiation stages, which can be deﬁned by
the expression of surface markers, such as the 2 types of inhibitory
receptors NKG2A and killer-cell immunoglobulin-like receptors
(KIRs).3,4 HumanNK cells seem to play an important antiviral role,
because patients with isolated NK-cell deﬁciencies exhibit an in-
creased susceptibility to herpes viruses.5 Furthermore, patients with
acute viral infections resulting from hantavirus, cytomegalovirus
(CMV), or chikungunya virus6-8 accumulate the late-differentiated
CD56dim NKG2C1 KIR1 NK-cell subset in peripheral blood.
However, none of these previous studies demonstrated a protective
role for speciﬁcally accumulated human NK-cell subsets against
virus-infected cells in vitro or in vivo.9,10
A ubiquitous persistent human virus, which has not been in-
vestigated in detail in this respect, is the primarily B-cell-tropic
Epstein-Barr virus (EBV). EBV is a g-herpes virus, which latently
infects the vast majority of the adult human population worldwide,
and is associatedwith B-cell and epithelial-cell malignancies.11 EBV
displays 2 modes of infection. One mode expresses latency genes
(latent EBV) leading toB-cell transformation in vitro and subsequent
generation of lymphoblastoid cell lines (LCLs). The other mode
expresses lytic genes (lytic EBV) leading to the production of in-
fectious viral particles and lysis of the host cell.12 Most primary
EBV infections occur before the age of 5 years and are usually
asymptomatic. Nevertheless, primary EBV infection occurring be-
yond this age may manifest as infectious mononucleosis (IM) that
affects around 10% of the population in Europe and the United
States.13,14 The usually self-limiting IM is characterized by a vig-
orous CD81 T-cell response that mainly targets EBV lytic epitopes15
and is associated with an increased risk of developing EBV-positive
classic Hodgkin lymphoma.16
The contribution of particular NK-cell subsets to the immune
control of EBV, especially during primary infection, remains elusive.
Here, we examined how blood NK-cell subsets accumulate and
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respond during IM, and to what extent they can recognize latently
and lytically EBV-infected B cells.
Material and methods
Study design
Twenty-two pediatric patients diagnosed with acute IM at the University
Children’s Hospital of Zurich were prospectively enrolled between October
2010 and April 2013. The onset date of symptoms was used as reference for
the longitudinal study. Twelve pediatric patients with IM symptoms, but
lacking the serological pattern compatible with acute EBV infection, were
also enrolled (IM-like) and donated peripheral blood at diagnosis. All serum
samples from IM-like patients were negative for HCMV DNA. Healthy
children and healthy adults aged 20 to 30 years were used as healthy
controls according to their EBV serology. Further details are outlined in the
supplemental Methods available on the BloodWeb site.
All participants provided informed consent in accordance with the
Declaration of Helsinki, and the institutional ethics committee approved all
protocols used.
Monoclonal antibodies and flow cytometry
Samples were acquired on a FACSCanto II and an LSR Fortessa (BD Bio-
sciences). Details about the handling of PBMCs, ﬂow cytometry analysis, and
antibodies used are described in the supplemental Methods.
Cell lines
Preparation of viral stocks, cell lines used, and induction and isolation of
lytic AKBM cells as well as the degranulation assay are described in the
supplemental Methods.
Viral loads quantification
EBV DNA levels were determined by real-time polymerase chain reaction.
The details of viral load measurements are outlined in the supplemental
Methods.
Statistical analysis
Datawere analyzed using Prism software (GraphPadSoftware, Inc.).P values
of ,.05 were considered signiﬁcant and were calculated with the non-
parametricMann-WhitneyU test or theWilcoxonmatched-pairs signed ranks
tests. Spearman’s rank correlation was used to examine associations between
2 quantitative values.
Results
Pediatric acute IM patients exhibit accumulation of activated
CD81 T cells and CD56dim NK cells
In young adults, IM is characterized by vigorous T-cell responses
mediated mainly by EBV-speciﬁc CD81 T cells.15 Nevertheless,
neither T-cell nor NK-cell responses in pediatric IM have been
characterized. Because we examined pediatric IM patients only,
we ﬁrst assessed the dynamics of the T-cell and NK-cell subset
responses in pediatric patients during the ﬁrst 6 months of IM.
Uninfected healthy individuals and pediatric patients with IM-like
diseaseswere used as controls. Acute IMpatients exhibited a twofold
increased median frequency of CD81 T cells (Figure 1A), a 15-fold
increased median frequency of activated CD81 T cells (Figure 1B),
and 60-fold increased median HLA-DR1 CD81 T-cell counts (data
not shown) comparedwith controls. The numbers of activated T cells
normalized within 6 months. These changes paralleled those of the
cellular EBV DNA levels through time (Figure 1C). Neither EBV
DNA levels nor frequency of CD81 T cells correlated with age
(supplemental Figure 1). Therefore, pediatric IMpatients as young as
2 years of age seem to exhibit the classic immunologic features found
in young adults with IM.
Moreover, we observed a 1.7-fold increase in the median
numbers of NK cells in acute IM compared with controls. These
numbers returned to baseline levels after 1 month (Figure 1D).
The blood NK-cell compartment is mainly composed of 2 well-
characterized functional subsets, the CD56bright CD162 and the
CD56dimCD161 subsets.17 The formerNK-cell subset produces large
amounts of cytokines on monokine stimulation, acquires cytotox-
icity only after prolonged activation, and is enriched in secondary
lymphoid organs.18 The latter NK-cell subset readily kills sus-
ceptible targets and can rapidly secrete IFN-g on engagement of
activating receptors.19 Acute IM patients displayed unchanged counts
of CD56bright CD162 NK cells (Figure 1F) and a 1.2-fold increase
in the median count of CD56dim CD161 NK cells (Figure 1H)
compared with controls. Interestingly, the intermediate NK-cell
subset CD56dimCD162 was increased in frequency during acute IM
(Figure 1E and supplemental Figure 2A) and exhibited a 3.7-fold
increase in median cell counts compared with controls (Figure 1G).
Thus we found a selective increase of the total CD56dim NK-cell
subset during acute IM.
Early-differentiated CD56dim NKG2A1 KIR2 NK cells accumulate
during IM and terminally differentiate as well as persist
afterward
To dissect the CD56dim NK-cell subset, we analyzed the expression
patterns of the inhibitory receptors NKG2A and KIRs, which might
allow assessment of subtle maturation stages spanning from early-
differentiated CD56dim NKG2A1 KIR2 to late-differentiated
CD56dim NKG2A2 KIR1 NK cells.3,4 Acute IM patients exhibited
a 1.8-fold increased median frequency of CD56dim NKG2A1 KIR2
NK cells (Figure 2A-B), but a 1.5-fold reduced median frequency of
CD56dim NKG2A2 KIR1 NK cells compared with EBV-negative
and EBV-positive control individuals (Figure 2C). Moreover,
acute IM patients displayed 4.8-fold and 3.5-fold increased median
absolute numbers of CD56dim NKG2A1 KIR2 NK cells compared
with EBV-negative and EBV-positive control individuals, respec-
tively (supplemental Figure 2B), but unchanged cell counts of the
late-differentiated CD56dim NKG2A2 KIR1 NK cells. We observed
no major changes in the frequencies and cell counts of the
CD56dim NKG2A2KIR2 and CD56dim NKG2A1KIR1NK-cell subsets
(supplemental Figure 2B-C). Furthermore, IM-like patients, that is,
patients with IM symptoms but no acute EBV infection, did not
exhibit NK-cell subset accumulation similar to that of IM patients.
We did not ﬁnd any differences in the frequency of this NK-cell
subset between EBV-seronegative and EBV-seropositive control
individuals. Surprisingly, the frequency of CD56dim NKG2A1KIR2
NK cells remained signiﬁcantly elevated in longitudinally followed
IM patients up to 6 months after acute IM, but returned to baseline
after 2 years (Figure 2B).
CD57 has been proposed as a marker of terminal differentiation
of NK cells3,20 and has been shown to be upregulated on CD56dim
NKG2C1 NK cells during acute infection with CMV, hantavirus,
or chikungunya virus.6-8 Therefore, we hypothesized that if the
accumulated CD56dim NKG2A1 KIR2 subset found in acute IM
patients is preferentially involved in the immune response against
EBV, it should acquire CD57 during the acute phase of IM to
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complete its terminal differentiation. Indeed, we observed a
2.5-fold increase in the median frequency of CD571 within the
CD56dim NKG2A1 KIR- subset from the acute IM phase to
1month later, but no changes in the CD56dimNKG2A2KIR1 subset
(Figure 2D-E, respectively). Thus, acute symptomatic EBV in-
fection elicits the speciﬁc accumulation of the CD56dim NKG2A1
KIR- NK-cell subset, its terminal differentiation, as well as its
persistence at higher frequency during the ﬁrst 6 months after
acute IM.
IM patients exhibit a stable KIR repertoire and unchanged
frequencies of CD56dim NKG2C1 NK cells
The KIR repertoire is composed of several activating and inhibitory
receptors speciﬁc for distinct groups of HLA class I alleles,21 is
Figure 1. Accumulation of activated HLA-DR1 CD81 T cells and
CD56dim NK cells during acute IM. PBMCs from healthy controls,
IM-like patients, and IM patients at acute phase (IM acute), at 1 (IM
1 month), and 6 months (IM 6 months) were analyzed by flow
cytometry. Frequencies of (A) CD81 T cells within the CD31 T-cell
population and (B) HLA-DR1 CD81 T cells within the CD81 T-cell
population in healthy controls (n 5 19), IM-like (n 5 11), and IM
acute (n 5 20), 1-month (n 5 10) and 6-month (n 5 7) patients. (C)
EBV DNA load in copies per 106 PBMCs in IM-acute (n 5 19),
1-month (n 5 14), and 6-month (n 5 9) patients. Counts (cells/mL
blood) of total NK cells (D) and frequencies of CD56bright CD162,
CD56dim CD162, and CD56dim CD161 NK-cell subsets within the
CD32 CD561 NK-cell population from representative healthy control,
IM-acute and 1-month patient (E). Counts (cells/mL blood) of (F)
CD56bright CD162, (G) CD56dim CD162, and (H) CD56dim CD161 NK
cells in healthy controls (n 5 31), IM-like patients (n 5 11), and
IM-acute (n 5 18), 1-month (n 5 10), and 6-month (n 5 8) patients.
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highly variable among individuals, and is stable throughout time
in healthy adults.22 Particular KIR receptors might be involved
in the immune control of viruses such as HIV,23-26 the hepatitis
C virus,27,28 or CMV.22,29 Therefore, to ensure that IM does
not lead to an accumulation of NK cells bearing speciﬁc KIRs,
we performed a comprehensive phenotypic KIR analysis30 in
a group of CMV-seronegative healthy controls and IM patients.
The KIR repertoire of IM patients remained stable throughout
the ﬁrst month of IM (Figure 3A), and the frequencies of single
KIR1CD56dim NK cells in IM patients were overall low compared
with controls (Figure 3B). Thus, IM is associated with the ac-
cumulation of a CD56dim NKG2A1 NK-cell subset, which does
not carry any increase in activating, nor inhibitory, KIR molecule
expression. Furthermore, CD56dim NK cells expressing NKG2C,
the activating counterpart of NKG2A,31 accumulate on CMV
infection,7,32,33 as well as on other viral infections in CMV-
positive individuals.6,8,34-36 Thus, we assessed whether a similar
accumulation occurs on EBV infection and therefore investigated
CMV-seronegative IM patients and controls to avoid bias as-
sociated with CMV carriage.37 We observed no changes in the fre-
quency ofNKG2C1NKcells within theCD56dimNKG2A2NK-cell
subset (Figure 3C-D) nor within the expanding CD56dim NKG2A1
KIR2 NK-cell subset (data not shown). Thus, CD56dim NKG2A1
KIR2 NKG2C2 NK cells accumulate during IM.
The preferential proliferation of CD56dim NKG2A1 KIR- NK cells
positively correlates with cellular EBV loads during acute IM
We next investigated whether the increase in the absolute numbers
of CD56dim NKG2A1 KIR- NK cells might be caused by active pro-
liferation of this NK-cell subset. We assessed the expression of the
proliferation marker Ki-67 in the CD56bright, the CD56dim NKG2A1
KIR2, and the CD56dim NKG2A2 KIR1 NK-cell subsets in acute IM
1month later.We found a twofold and a threefold increase in themedian
frequencyofKi-671 cellswithin theCD56dimNKG2A1KIR2NKcells
in acute IM compared with controls and IM at 1 month, respectively
(Figure 4A-B). However, we did not observe any increased proliferation
in the more differentiated NKG2A2KIR1NK subset, and there was no
difference when comparing EBV-negative with EBV-positive controls
(Figure 4A-B and data not shown). In addition, the precursor CD56bright
NK-cell subset, which exhibits strong proliferation properties and
responds tominute doses of cytokines in vitro, did not showan increased
frequency of Ki-671 cells in acute IM patients (Figure 4B). Notably, the
frequencies of proliferating Ki-671 cells within the CD56dim NKG2A1
KIR-positively correlatedwithEBVDNAlevels inPBMCs(Figure4C),
but not in serum (data not shown). No such correlation was observed
within the CD56dim NKG2A2KIR1NK-cell subset. This suggested
that EBV-infected B cells in IM patients might directly drive the pro-
liferation of early-differentiated CD56dim NK cells. We next asked
Figure 2. Accumulation and terminal differentiation
of the CD56dim NKG2A1 KIR2 NK-cell subset during
acute IM. PBMCs from controls and IM patients were
analyzed by flow cytometry. (A) Frequencies of CD56dim
NKG2A1 KIR2 NK cells within the CD56dim population
from representative healthy control, IM-acute, 1-month,
and 6-month patients. Frequencies of (B) CD56dim
NKG2A1 KIR2 and (C) CD56dim NKG2A2 KIR1 NK cells
in healthy EBV-negative controls (n 5 17), healthy EBV-
positive controls (n 5 20), IM-like patients (n 5 12), and
IM-acute (n 5 17), 1-month (n 5 11), 6-month (n 5 10),
and 2-year (n 5 4) patients. Frequencies of CD571 cells
within (D) the CD56dim NKG2A1 KIR2 and (E) the
CD56dim NKG2A2 KIR1 NK-cell subsets in healthy
EBV-negative controls (n 5 17), healthy EBV-positive
controls (n 5 20), and IM-acute (n 5 17), 1-month
(n 5 11), 6-month (n 5 10), and 2-year (n 5 4)
patients. Horizontal lines or single symbols indicate
median values. Error bars indicate interquartile ranges.
Mann-Whitney U tests.
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whether theproliferationof theCD56dimNKG2A1KIR2NK-cell subset
differs according to CD57 expression. Surprisingly, proliferation was
exclusively found within the CD57- fraction (Figure 4D-E). Our
ﬁnding aligns with previous studies showing a decreased proliferative
potential of CD571 NK cells compared with CD572 NK cells.3,20
Thus, CD56dim NKG2A1KIR2 CD572NK cells seem to proliferate
preferentially during acute IM but not 1 month later. Moreover, in the
acute phase, proliferation parallels the accumulation of this NK-cell
subset, which displays a sevenfold and a 4.8-fold median increase
compared with EBV-negative and EBV-positive controls, respec-
tively (Figure 4F). In addition, CMV status did not seem to inﬂuence
the NK-cell response (supplemental Figure 3).We did not observe any
correlation between the count of the CD56dimNKG2A1KIR2CD572
NK cells, nor the count of total NK cells, and the EBV DNA levels in
PBMCs or in serum (data not shown). Thus, early-differentiated NK
cells accumulate in IM patients after EBV-driven proliferation.
CD56dim NKG2A1 KIR2 NK cells preferentially target
EBV-infected B cells with lytic reactivation
CD56dimNKG2A1KIR2NKcells are functional againstHLA-class-
I-deﬁcient target cells, including the EBV-positive LCL 721.221 cell
line,4 but their reactivity toward HLA class I competent autologous
LCLs has not yet been assessed.Weobserved a lowoverall frequency
of degranulating NK cells on coculture with autologous LCLs.
Nevertheless, the CD56dim NKG2A1 KIR2 NK subset, which ac-
cumulates during IM, displayed a more than twofold increase in
degranulation compared with the CD56bright and CD56dim NKG2A2
KIR1 NK-cell subset (Figure 5A). In contrast, the EBV-negative
allogeneic B-cell line L428, which exhibits an activated phenotype
comparable to LCLs, elicits an increased response in the CD56dim
NKG2A2 KIR1 NK subset only (Figure 5B). This low NK-cell re-
sponse against autologous LCLsmight be a result of their high surface
level of HLA class I and HLA-E which might engage the NK-cell
inhibitory receptors KIR and NKG2A, respectively. Indeed, EBV-
infected B cells upregulated HLA class I38 and HLA-E (Figure 5C).
On the other hand, induction of the lytic cycle of EBV infection
has been shown to sensitize EBV-infected B cells to NK-cell killing
using the EBV-positive Akata Burkitt lymphoma reporter cell line
AKBM,39 which allows the puriﬁcation of Akata Burkitt lymphoma
cells with and without EBV lytic reactivation, respectively. Hence, we
tested the degranulation of the CD56dim NKG2A1 KIR2 NK subset
against either latent AKBM or lytic AKBM cells from convalescent
Figure 3. Frequencies of single KIR-positive and
NKG2C1 CD56dim NK cells are not altered during
acute IM. (A) Frequencies of CD56dim NKG2A2 NK
cells expressing the 7 analyzed KIRs from 1 repre-
sentative CMV-seronegative IM patient at acute phase
and at 1 month. The presence of 1 KIR in a combination
is represented by a color code below the graph.
(B) Frequencies of single KIR-positive CD56dim NK cells
in healthy controls (Ctl, n 5 11) and IM patients
(n 5 10) at acute phase (A) and at 1 month (M1). (C)
Frequencies of NKG2C1 CD571 NK cells within the
CD56dim NKG2A2 population from 1 CMV-seronegative
and 1 CMV-seropositive IM patient at acute phase
and at 1 month. (D) Frequencies of NKG2C1 NK cells
within the CD56dim NKG2A2 NK cell population
in CMV-seronegative healthy controls (n 5 13),
CMV-seronegative (n 5 10), and CMV-seropositive
(n 5 5, red) IM patients at acute phase and at
1 month (n 5 2 for CMV-seropositive, red lines).
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IM patients and healthy EBV-positive controls and compared it to the
CD56bright and the CD56dim NKG2A2 KIR1 subsets. To avoid HLA
class I/KIR mismatch bias, we speciﬁcally assessed the degranulation
in KIR1 matched (KIR2DL2/DL3/3DL11) NK cells according to
the AKBM genotype (Bw4/C1/C1). We could conﬁrm increased
responses of NK cells against lytic compared with latent AKBM
cells (Figure 5D-F) previously shown to be mediated by a down-
regulation of the inhibitory ligands HLA-class I and HLA-E and
an upregulation of the activating ligands CD112 and ULBP-1.39
Similarly, we also found increased expression of activating ligands
Figure 4. Increased count of CD56dim NKG2A1
KIR2 CD572 NK cells during acute IM is caused
by preferential proliferation. (A) Representative exam-
ples of costaining for NKG2A and Ki-67 and costaining
for KIR and Ki-67 on CD56dim NK cells in healthy control
and IM-acute and 1-month patients. (B) Frequencies of
Ki-671 cells within the CD56bright, CD56dim NKG2A1
KIR2, and CD56dim NKG2A2 KIR1 NK-cell subsets in
healthy controls (n 5 21), in IM-acute (n 5 15), and in
1-month patients (n 5 7). (C) Correlation of EBV DNA
loads (copies per 106 PBMCs) and frequencies of
Ki-671 cells within the CD56dim NKG2A1 KIR2 NK-cell
subset from acute IM patients. Spearman r 5 0.53,
P (2-tailed) 5 .042. (D) Representative example of
costaining for CD57 and Ki-67 on CD56dim NKG2A1
KIR2 NK cells in an IM-acute and 1-month patient.
(E) Frequencies of Ki-671 cells within the CD56dim
NKG2A1 KIR2 NK cells according to CD57 expression
in healthy controls (n 5 15), IM-acute (n 5 9), and
1-month (n 5 4) patients. (F) Count of CD56dim
NKG2A1 KIR2 CD572 in healthy EBV-negative controls
(n 5 14), healthy EBV-positive controls (n 5 17), IM-like
(n 5 11), IM-acute (n 5 17), 1-month (n 5 10), and
6-month (n 5 8) patients. Horizontal lines indicate
median values of a given symbol. Mann-Whitney
U tests.
2538 AZZI et al BLOOD, 16 OCTOBER 2014 x VOLUME 124, NUMBER 16
For personal use only.on October 22, 2014. by guest  www.bloodjournal.orgFrom 
on lytic EBV infected LCLs (supplemental Figure 4D-G), however
the expression of the respective activating receptors in the CD56dim
NKG2A1 KIR2 NK-cell subset was unaltered in IM patients
(supplemental Figure 4A-C). Importantly, the CD56dim NKG2A1
KIR2 NK-cell subset exhibited a signiﬁcantly stronger degranulation
against lytic AKBM cells compared with all other subsets
(Figure 5F). We found no difference in the degranulation capacity
of CD56dim NKG2A1 KIR2 NK between convalescent IM patients
and controls, suggesting that these NK cells are functional and
are not in an exhausted state in the aftermath of acute IM. Thus,
Figure 5. Increased cytotoxic degranulation of the
CD56dim NKG2A1 KIR2 NK subset against EBV-
infected B cells with lytic replication. (A) PBMCs
from 6 healthy EBV-positive donors were cocultured
with autologous LCLs and (B) EBV-negative L428 at an
effector to target ratio of 10:1 for 6 hours. Frequencies
of degranulating (CD107a1) cells within the CD56bright
(Bright), the CD56dim NKG2A1 KIR2 (Dim N1/K2),
and the CD56dim NKG2A2 KIR1 (Dim N2/K1) NK-cell
subsets were assessed by flow cytometry at the end of
the coculture. (C) HLA class I and HLA-E expression on
CD191 B cells from PBMCs (light gray histogram) and
from autologous LCLs (dark gray histogram). Isotype
controls are depicted as a white histogram. (D)
Representative example of frequencies of CD107a1
NK cells within the 3 NK-cell subsets after coculture
with latent AKBM or lytic AKBM. Frequencies of
degranulating (CD107a1) NK cells within the CD56bright
(Bright), the CD56dim NKG2A1 KIR2 (Dim N1/K2) and
the CD56dim NKG2A2 matched KIR1 (Dim N2/K1) NK-
cell subsets in PBMCs from 3 convalescent IM patients
(open symbols) and 3 healthy EBV-positive donors
(filled symbols) cocultured with (E) latent AKBM or (F)
lytic AKBM (n 5 6). Horizontal lines indicate median
values of a given subset, Wilcoxon matched-pairs signed
ranks tests.
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CD56dim NKG2A1 KIR2 NK cells preferentially recognize lytic
EBV-replicating B cells.
EBV lytic replication triggers in vitro proliferation of
NKG2A1 KIR- NK cells
Finally, we examined the proliferation of NKG2A1 KIR2 NK cells
using staining for Ki-6740 in an in vitro model of primary EBV
infectionof cord bloodmononuclear cells (CBMC) infectedwith either
wild-type (WT) EBV or lytic replication incompetent BZLF1-KO
(BZ1KO) EBV. Both viruses elicited similar IFN-type I responses
24 hours postinfection (Figure 6A) and exhibited comparable infec-
tion capacity, as evaluated by the frequencies ofGFP1EBV-infected
B cells 3 days postinfection (Figure 6B). Because most NK cells
upregulated CD56 surface expression during in vitro culture
(Figure 6C, ﬁrst row), we did not distinguish between the CD56bright
Figure 6. EBV-driven in vitro proliferation of NKG2A1 KIR- NK cells
partially depends on expression of lytic antigens. Proliferation of
NK-cell subsets was assessed 7 days after inoculation of CBMCs
with either WT EBV, BZLF1-KO (BZ1KO) EBV or PBS (MOCK). (A)
Concentrations of IFN-a in supernatant 24-hour postinoculation on
MOCK, WT EBV, and BZ1KO EBV infection (pg/mL; n 5 5). (B)
Representative example of CD19 and GFP costaining within live
lymphocytes 72 hours postinfection. Numbers indicate frequencies of
GFP-negative or GFP-positive cells within the CD191 B-cell popula-
tion. (C) Frequencies of Ki-671 NKG2A1 KIR2 NK cells 7 days after
inoculation of CBMCs with mock, WT EBV, or BZ1KO EBV, or after
stimulation with IL-2. The depicted gates were assessed within live
lymphocytes (first row), CD32 CD561 NK cells (second row), and
NKG2A1 KIR2 NK cells (third row). (D) Ratio of NKG2A1 KIR2 Ki-671
NK-cell counts from WT EBV- or BZ1KO EBV- over mock-infected
CBMCs. (E) Frequencies of CD56dim NKG2A1 KIR2 NK cells in
newborns (n 5 8), children aged 1 to 5 years (n 5 16), children aged
5 to 15 years (n 5 17), and adults aged 20 to 30 years (n 5 15). (F)
Counts of CD56dim NKG2A1 KIR- NK cells in children aged 1 to 5 years
(n 5 14), children aged 5 to 15 years (n 5 15), and adults aged 20 to
30 years (n 5 15). Horizontal lines indicate median values of a given
age group, Mann-Whitney U tests.
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andCD56dimNKcells for further analysis.We observed an increased
proliferation of NKG2A1KIR2NK cells 7 days after infection with
WT EBV compared with mock (Figure 6C-D). Infection with
BZ1KO EBV, with abolished expression of all EBV lytic antigens,
elicited a twofold-reduced proliferation ofNKG2A1KIR2NKcells,
in comparison withWTEBV (median ratio 2.9 vs 6.3,P5 .04). This
indicates that the proliferation of NKG2A1KIR2NK cells partially
depends on the presence of EBV-infected cells expressing lytic
antigens. Notably, NKG2A2 KIR1 NK cells exhibit similar
proliferation on infection with WT EBV, but this is not affected by
the absence of lytic antigens (data not shown). Finally, we assessed
a possible age-dependent distribution of this early-differentiated
NK-cell subset in peripheral blood from healthy individuals that
might correlate with the known age-dependent prevalence of prima-
ry symptomatic EBV infection. Indeed, CD56dim NKG2A1 KIR2
NK cells both decreased in frequency (Figure 6E) and in absolute num-
bers (Figure 6F) during the ﬁrst decade of life, whereas the counts of
CD56dimNKG2A2KIR1NKcells remained unchangedwith age (data
not shown).Thus,CD56dimNKG2A1KIR2NKcells,which decrease
in frequency in the ﬁrst decade of life, preferentially degranulate and
proliferate in response to lytic EBV-replicating B cells.
Discussion
Here we demonstrate in longitudinally followed pediatric IM
patients that an early-differentiated CD56dim NKG2A1 KIR2 NK
subset selectively accumulates during primary symptomatic EBV
infection and persists at increased frequencies formonths.Moreover,
our data indicate that these NK cells speciﬁcally recognize B cells
undergoing lytic EBV replication. Our ﬁndings are unprecedented
and suggest that responses of NK-cell subsets to viral infections may
not be conﬁned to late-differentiated populations.6-8 Moreover,
distinct NK-cell subsets may be rather pathogen-speciﬁc.
Remarkably, althoughwe found increased counts in the cytotoxic
CD56dim NK-cell subset, but not in the less-differentiated CD56bright
CD16- NK-cell subset, we could not conﬁrm the previously reported
expansion of CD56bright CD161NK cells during acute symptomatic
EBV infection.41 We rather observed an unusual increase of the
intermediate CD56dim CD162 NK-cell subset, which might be
explained by downregulation of CD56 on CD56bright NK cells or by
downregulation ofCD16 such as observed in degranulatingCD56dim
NK cells on coculture with K562 cells (unpublished observations).
This CD56dim NK-cell subset is distinctly characterized by NKG2A
expression and by the absence of KIRs. It strikingly differs from
that of other acute viral infections such as CMV, hantavirus, or
chikungunya virus infection,6-8 inwhich theCD56dimKIR1NKG2C1
NK-cell subset was shown to be expanded. CD56dim NKG2A1 KIR-
NK cells are considered early-differentiated4 as suggested by the
speciﬁc temporal reconstitution of the NK-cell subsets in hemato-
poietic stem-cell transplanted patients42-44 and in mice with human
immune-system components.3 Based on our results, ongoing dif-
ferentiation of these early-differentiated NK cells seems to occur
during the ﬁrst weeks of IM; this is further supported by studies in
EBV-infected mice with human immune-system components.45
Another striking feature of the IM-associated NK-cell response is
the persistence of elevated frequencies of the CD56dim NKG2A1
KIR- NK cells for up to 6 months after CD81 T-cell numbers
have normalized. Nevertheless, we observed no difference in the
peripheral blood frequencies of these NK cells between EBV-
seropositive and EBV-seronegative control individuals, contrasting
the situation after CMV infection where late differentiated NK cells
persist at increased levels.32 This might be explained by compart-
mentalized NK-cell accumulation during asymptomatic EBV in-
fection, as has been proposed for EBV-speciﬁc T-cell responses
in the tonsils,47,48 and suggests that the acute symptomatic EBV
infection systemically imprints theNK-cell compartment differently.
Accordingly, CD56bright NKG2A1 and mostly KIR- NK cells were
found enriched in tonsils of EBV-seropositive compared with EBV-
seronegative individuals.49 Indeed, this could result from ongoing
lytic EBV replication at these sites in asymptomatic EBV carriers.46
Additionally, we determined that the increased CD56dim NKG2A1
KIR- NK-cell numbers during acute IMwere caused by the selective
proliferation of this subset. Such selectivity has not been reported
to our knowledge during other acute viral infections. Because
the CD56dim NKG2A1 KIR2 NK subset only actively proliferated
during the acute phase of IM and was only increased in absolute
numbers at this stage, the persistently increased frequency of this
subsetmight be caused by either a longer survival of theseNKcells in
peripheral blood or a continuous EBV-driven proliferation in tissues
followed by recruitment and accumulation in the peripheral blood.
Indeed, the numbers of EBV-infected B cells quickly decrease in
the peripheral blood after acute IM,50 and EBV turns off antigen
expression in these cells.51 Thus, an EBV-driven proliferation of NK
cells during IM convalescence might not be expected in peripheral
blood. Nevertheless, IM patients exhibit prolonged oral EBV
shedding up to 1 year after IM,14,52 indicating that EBV replication
occurs in the oropharynx. This, in turn, may result in local EBV-
driven proliferation of NK cells after IM that are subsequently
recruited in peripheral blood.
Several lines of evidence support the hypothesis that EBV-
infected B cells, and not proinﬂammatory cytokines, directly
drive the unique proliferation of early-differentiated NK cells:
ﬁrst, a similar expansion is not observed in patients with IM-like
symptoms; second, the precursor CD56bright NK-cell subset, which
possesses strong proliferative responses to cytokines, does not
display an enhanced proliferation during acute IM; third, the
frequency of proliferating early-differentiated NK cells positively
correlates with EBV loads in blood cells. On the other hand, we did
not observe any correlation between overall NK-cell counts and viral
load. These ﬁndings are in conﬂict with previous studies reporting
a negative correlation between NK-cell frequencies and counts and
cellular EBVDNA levels41 or a positive correlation betweenNK-cell
counts and EBV DNA levels in whole blood.14 Hence, acute IM
elicits the proliferation ofCD57-CD56dimNKG2A1KIR2NKcells,
which then differentiate to become CD57 positive. A fraction of
this subset might represent antigen-experienced NK cells that
speciﬁcally responded to EBV-infected cells in a similar fashion
as during MCMV infection of experimental mice in which these
NK cells are suggested to constitute memory NK cells.2,53
These early-differentiated NK cells exhibit enhanced degranula-
tion against EBV-infected B cells with lytic reactivation. Reduced
HLA-E-mediated inhibitory signals on EBV-infected cells express-
ing lytic antigensmight lead to preferential recognition byNKG2A1
NK cells and could be caused by decreased availability of class I
leader signal peptide39 or via direct modulation of HLA-E by EBV-
derived peptides.54 In addition to these diminished inhibitory signals,
we and others have observed an increased expression of activating
ligands in lytic EBV infection,39 and NKG2D and DNAM1 have
been identiﬁed as the main activating NK-cell receptors for the
recognition of B cells with lytic EBV infection in vitro.39 In good
agreement, loss of NKG2D function has been found to confer sus-
ceptibility to uncontrolled EBV infection and neoplasia in XMEN
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patients in vivo.55 How lytic EBV infection leads to the upregulation
of activating ligands, however, remains unclear. NKG2D ligands have
been reported to be upregulated on induction of the DNA damage
response and cytosolic DNA recognition.56 Although EBV, like other
herpes viruses, packages its DNA into the viral capsid in the nucleus
during lytic replication, some of it might become accessible during
capsid transit through the cytosol and trigger this pathway of NKG2D
ligand upregulation. Newly infected B cells transiently express sever-
al lytic antigens, mostly from the immediate early and early lytic
genes,57 and some of these antigens might contribute to the prolifera-
tion of NKG2A1 KIR2 NK cells on EBV infection of CBMCs.
We suggest that CD56dim NKG2A1 KIR- NK cells preferentially
recognize autologous B cells with lytic EBV infection, and that rec-
ognition of lytic EBV replication drives the characteristic NK-cell
accumulation that we observed in acute IM patients. Because IM only
manifests in older children, adolescents, and young adults with
decreased frequencies of this herein newly described EBV-reactive
NK-cell subset, we postulate an age-dependent impaired NK-cell-
mediated immune control of EBV infection as one possible cause
of IM.
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